Cell therapy developer ArsenalBio raises $325 million
Drug Discovery World
SEPTEMBER 19, 2024
Arsenal Biosciences has closed an oversubscribed $325 million Series C financing round to support its development of CAR T-cell therapies for solid tumours. The funding round included new investors ARCH Venture Partners, Milky Way Investments Group, Regeneron Ventures, NVentures (NVIDIA’s venture capital arm), Luma Group, funds and accounts advised by T Rowe Price Associates, Rock Springs Capital, among others.
Let's personalize your content